Royalty Pharma Plc (RPRX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $39.85B
Last updated: Nov 17, 2026 at 11:06 AM ET
Royalty Pharma Plc (RPRX) Financials: Revenue, Profit and Cash Flow
Royalty Pharma Plc reported revenue of $2.38B for the fiscal year ended Dec 31, 2025, up 5.1% from the year before. That year, net income was $1.32B with a net margin of 55.7%, operating cash flow was $2.49B and free cash flow was $2.49B. The quarter ended Sep 30, 2026 had revenue of $690.10M and net income of $266.64M.
Revenue and Margins
The operating margin was 65.6% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $1.88B, a compound annual rate of 2.7%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $2.38B | +5.1% | 100.0% | 65.6% | 55.7% |
| Dec 2024 | $2.26B | -3.9% | 100.0% | 57.1% | 58.8% |
| Dec 2023 | $2.35B | +5.2% | 100.0% | 63.4% | 72.2% |
| Dec 2022 | $2.24B | -2.3% | 100.0% | 13.7% | 10.3% |
| Dec 2021 | $2.29B | +7.9% | 100.0% | 62.5% | 54.2% |
| Dec 2020 | $2.12B | +17.0% | 100.0% | 75.2% | 80.2% |
| Dec 2019 | $1.81B | +1.1% | 100.0% | 144.6% | 135.7% |
| Dec 2018 | $1.79B | +12.3% | 100.0% | 76.0% | 84.6% |
| Dec 2017 | $1.60B | -14.9% | 100.0% | 58.8% | 75.7% |
| Dec 2016 | $1.88B | N/A | 100.0% | 38.5% | 30.1% |
Income Statement
In the fiscal year ended Dec 2025, net income fell 0.8% from the year before. In the quarter ended Sep 2026, net income fell 39.4% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.38B | $2.26B | $2.35B | $2.24B | $2.29B | $2.12B | $1.81B | $1.79B | $1.60B | $1.88B |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $33.27M | $0 |
| Gross profit | $2.38B | $2.26B | $2.35B | $2.24B | $2.29B | $2.12B | $1.81B | $1.79B | $1.60B | $1.88B |
| Research and development | $452.00M | $2.00M | $52.00M | $177.11M | $200.08M | $26.29M | $83.04M | $392.61M | $117.87M | $91.02M |
| Operating income | $1.56B | $1.29B | $1.49B | $307.06M | $1.43B | $1.60B | $2.62B | $1.36B | $939.69M | $722.87M |
| Net income | $1.32B | $1.33B | $1.70B | $230.06M | $1.24B | $1.70B | $2.46B | $1.52B | $1.21B | $565.91M |
| EBITDA | $1.57B | $1.48B | $1.79B | $354.33M | N/A | $1.81B | $2.76B | $1.81B | $1.62B | $1.07B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $690.10M | $674.14M | $630.58M | $621.99M | $609.29M | $578.66M | $568.25M | $593.64M | $564.69M | $537.27M | $567.98M | $596.07M |
| Gross profit | $690.10M | $674.14M | $630.58M | $621.99M | $609.29M | $578.66M | $568.25M | $593.64M | $564.69M | $537.27M | $567.98M | $596.07M |
| Operating income | $410.84M | $133.12M | $563.04M | $388.38M | $427.16M | $209.80M | $534.18M | $361.51M | $735.07M | $269.63M | -$73.77M | $612.90M |
| Net income | $266.64M | $81.49M | $468.26M | $355.91M | $440.21M | $92.64M | $434.43M | $334.35M | $806.36M | $194.38M | -$4.27M | $717.59M |
Balance Sheet
As of Dec 2025, total debt of $8.95B exceeded cash and equivalents by $8.33B.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $19.62B | $18.22B | $16.38B | $16.81B | $17.52B | $16.02B | $12.45B | $11.37B | $11.37B | $10.48B |
| Current assets | $1.53B | $1.80B | $1.27B | $2.55B | $2.88B | $2.70B | $832.07M | $2.61B | $2.95B | $3.00B |
| Cash and equivalents | $618.70M | $929.03M | $477.01M | $1.71B | $1.54B | $1.01B | $246.20M | $1.92B | $1.38B | $1.67B |
| Total liabilities | $9.91B | $7.88B | $6.30B | $7.29B | $7.27B | $6.12B | $6.31B | $6.82B | $6.90B | $6.02B |
| Short-term debt | $380.00M | $997.77M | $0 | $997.51M | $0 | $281.98M | $281.98M | $281.44M | $280.93M | $172.68M |
| Long-term debt | $8.57B | $6.61B | $6.14B | $6.12B | $7.10B | $5.82B | $5.96B | $6.24B | N/A | N/A |
| Shareholder equity | $6.48B | $6.95B | $6.53B | $5.63B | $5.78B | $4.82B | $2.82B | $4.49B | $4.46B | $4.45B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $19.46B | $19.82B | $19.82B | $19.62B | $19.35B | $18.32B | $17.61B | $18.22B | $18.04B | $17.66B | $16.13B | $16.38B |
| Total liabilities | $9.67B | $10.03B | $9.88B | $9.91B | $9.73B | $8.82B | $7.82B | $7.88B | $7.78B | $7.90B | $6.27B | $6.30B |
| Cash and equivalents | $513.66M | $811.99M | $586.39M | $619.00M | $938.94M | $631.91M | $1.09B | $929.03M | $950.05M | $1.76B | $843.00M | $477.01M |
| Shareholder equity | $6.84B | $6.83B | $6.89B | $6.48B | $6.41B | $6.35B | $6.69B | $6.95B | $6.87B | $6.48B | $6.50B | $6.53B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 100.0% of operating cash flow. Dividends and share repurchases together came to 85.5% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $2.49B | $2.77B | $2.99B | $2.14B | $2.02B | $2.03B | $1.67B | $1.62B | $1.42B | -$15.58M |
| Capital expenditures | $0 | $0 | $2.12B | $2.04B | $523.00K | $2.20B | $1.72B | $269.59M | $2.29B | $0 |
| Free cash flow | $2.49B | $2.77B | $872.28M | $102.83M | $2.02B | -$162.37M | -$54.05M | $1.35B | -$872.39M | -$15.58M |
| Dividends paid | $900.63M | $863.90M | $854.85M | $950.70M | $918.59M | $1.12B | $893.36M | $1.08B | $735.17M | N/A |
| Share repurchases | $1.23B | $229.65M | $304.76M | $0 | $0 | N/A | $4.27M | $0 | N/A | N/A |
| Investing cash flow | -$1.61B | -$2.68B | -$2.07B | -$1.03B | -$1.87B | -$2.76B | -$2.15B | $303.42M | -$1.59B | N/A |
| Financing cash flow | -$1.19B | $361.14M | -$2.15B | -$944.86M | $385.11M | $1.49B | -$1.19B | -$1.38B | -$123.25M | $2.88M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $686.08M | $728.46M | $718.23M | $827.15M | $702.62M | $363.98M | $596.08M | $742.52M | $703.61M | $658.21M | $664.64M | $772.63M |
| Capital expenditures | N/A | N/A | $0 | $0 | $1.11M | $0 | $0 | $0 | $832.71M | $746.63M | $86.08M | $1.00B |
| Free cash flow | N/A | N/A | $718.23M | $827.15M | $701.50M | $363.98M | $596.08M | $742.52M | -$129.10M | -$88.42M | $578.55M | -$229.61M |
Frequently Asked Questions About RPRX
What is Royalty Pharma Plc's annual revenue?
Royalty Pharma Plc reported revenue of $2.38B for the fiscal year ended Dec 31, 2025.
How fast is Royalty Pharma Plc's revenue growing?
Revenue was up 5.1% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 2.1%.
Is Royalty Pharma Plc profitable?
Yes. Royalty Pharma Plc reported net income of $1.32B for the fiscal year ended Dec 31, 2025, with a net margin of 55.7%.
How much free cash flow does RPRX generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $2.49B minus capital expenditures of $0 produced free cash flow of $2.49B.
How much debt does Royalty Pharma Plc have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $8.57B, short-term debt of $380.00M and cash and equivalents of $618.70M.
RPRX pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors